M J Edelman
Affiliation: University of Maryland
Edelman M, TAN M, Fidler M, Sanborn R, Otterson G, Sequist L, et al
. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol. 2015;33:189-94 pubmed publisher
..The median PFS for the control arm was 97 days (95% CI, 52 to 193 days) versus 85 days (95% CI, 67 to 142 days) for the experimental arm (P = .91). Apricoxib did not improve PFS, despite biomarker-driven patient selection. ..
Edelman M, Watson D, Wang X, Morrison C, Kratzke R, Jewell S, et al
. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008;26:848-55 pubmed publisher
..However, a prospectively defined subset analysis suggests an advantage for celecoxib and chemotherapy for patients with moderate to high COX-2 expression. ..
Bhooshan N, Staats P, Fulton A, Feliciano J, Edelman M. Prostaglandin E Receptor EP4 expression, survival and pattern of recurrence in locally advanced NSCLC. Lung Cancer. 2016;101:88-91 pubmed publisher
..There was a significant correlation between OS and nuclear EP4 expression, indicating that this is a potential therapeutic target. Studies with AT-007, a specific inhibitor of EP4, are planned to commence this year. ..
Edelman M, Hodgson L, Rosenblatt P, Christenson R, Vokes E, Wang X, et al
. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012;7:649-54 pubmed publisher
..0255 and p = 0.0068). CYFRA and change in CYFRA were found to be reliable markers for response to chemotherapy for NSCLC; however, a precise threshold to mark response has yet to be determined. ..
Edelman M, Lapidus R, Feliciano J, Styblo M, Beumer J, Liu T, et al
. Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016;78:959-967 pubmed
..Combinations with other platinum agents (e.g., carboplatin) should be considered. This is the first fully reported human trial of KML-001. ..
Edelman M. Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials. Clin Lung Cancer. 2003;4 Suppl 2:S40-4 pubmed
..Its excellent toxicity profile has also led several groups to utilize the regimen as a platform for combination with newer drugs...
Edelman M. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer. 2005;7 Suppl 2:S64-6 pubmed
..This article will review the rationale for the use of bortezomib as part of the chemotherapy/RT strategy for the treatment of NSCLC...
Edelman M, Schneider C, Tsai C, Kim H, Quoix E, Luft A, et al
. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. J Clin Oncol. 2013;31:1990-6 pubmed publisher